MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy

Reuters01-14

<a href="https://laohu8.com/S/MBX">MBX Biosciences</a> Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy

MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603595006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603595006","market":"us","top_or_hot":-1,"title":"MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a> Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a> Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBX","symbol_name":"MBX Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL9p2YKN:1","article_id":"2603595006","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603595006","pubTimestamp":1768349027,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBX":"MBX Biosciences","BK4007":"制药"},"translate_title":"MBX Biosciences公布Canvuparatide治疗甲状旁腺功能减退症的2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBX":0.9},"content_text":"MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy\n    \n\n        MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603595006","isCrawlerRequest":true}